Folger Nolan Fleming Douglas Capital Management Inc. Acquires 120 Shares of Danaher Co. (NYSE:DHR)

Folger Nolan Fleming Douglas Capital Management Inc. grew its holdings in Danaher Co. (NYSE:DHR) by 3.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,037 shares of the conglomerate’s stock after acquiring an additional 120 shares during the period. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Danaher were worth $927,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Decker Retirement Planning Inc. acquired a new position in Danaher during the fourth quarter worth $31,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Danaher in the 3rd quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. acquired a new stake in Danaher in the 3rd quarter worth approximately $40,000. FSA Wealth Management LLC bought a new stake in Danaher during the third quarter worth approximately $50,000. Finally, Darwin Wealth Management LLC acquired a new position in Danaher during the third quarter valued at approximately $55,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on DHR shares. Citigroup decreased their price objective on shares of Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a report on Monday, January 6th. Evercore ISI raised their price target on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Stifel Nicolaus lifted their price objective on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price for the company in a research note on Friday, December 13th. Finally, Scotiabank assumed coverage on Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $286.80.

Danaher Stock Performance

NYSE:DHR opened at $238.41 on Friday. The firm has a market capitalization of $172.20 billion, a PE ratio of 45.50, a price-to-earnings-growth ratio of 4.23 and a beta of 0.83. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher Co. has a 12-month low of $222.53 and a 12-month high of $281.70. The firm has a 50-day moving average price of $234.99 and a 200 day moving average price of $253.37.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the prior year, the firm posted $2.02 EPS. Danaher’s quarterly revenue was up 3.1% compared to the same quarter last year. Research analysts anticipate that Danaher Co. will post 7.49 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is currently 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.